CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?
CRISPR Therapeutics Ownership Summary
CRISPR Therapeutics is owned by 3.86% institutional investors, 1.75% insiders, and 94.39% retail investors. Ark investment management is the largest institutional shareholder, holding 10.53% of CRSP shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 8.37% of its assets in CRISPR Therapeutics shares.
CRSP Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | CRISPR Therapeutics | 3.86% | 1.75% | 94.39% |
| Sector | Healthcare Stocks | 279.42% | 10.64% | -190.05% |
| Industry | Biotech Stocks | 64.05% | 10.69% | 25.27% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Ark investment management | 8.97M | 10.53% | $353.18M |
| Capital investors | 8.74M | 10.26% | $344.15M |
| T. rowe price investment management | 3.81M | 4.47% | $150.03M |
| Blackrock | 2.78M | 3.40% | $150.03M |
| Blackrock funding, inc. /de | 2.76M | 3.24% | $108.61M |
| Sumitomo mitsui trust | 2.75M | 3.22% | $108.07M |
| Nikko asset management americas | 2.75M | 3.22% | $108.07M |
| State street | 2.49M | 2.95% | $98.07M |
| Fmr | 2.22M | 2.61% | $87.51M |
| Ubs group | 1.98M | 2.33% | $78.09M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Versant venture management | 498.56K | 22.62% | $19.62M |
| Sr one capital management, lp | 1.05M | 10.07% | $41.29M |
| Spear rsc | 165.00K | 6.29% | $8.91M |
| Nea management company | 1.59M | 4.16% | $54.03M |
| Ark investment management | 8.97M | 2.94% | $353.18M |
| Contrarius investment management | 685.72K | 2.32% | $37.04M |
| Ecor1 capital | 1.39M | 2.07% | $54.68M |
| Eagle health investments lp | 197.00K | 1.87% | $10.64M |
| Nikko asset management americas | 2.75M | 1.17% | $108.07M |
| Green alpha advisors | 24.63K | 0.78% | $969.40K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Orbis allan gray | 1.48M | 0.31% | 1.48M |
| Ark investment management | 8.97M | 2.94% | 1.47M |
| Ubs group | 1.98M | 0.01% | 1.31M |
| T. rowe price investment management | 3.81M | 0.09% | 1.07M |
| Capital investors | 8.74M | 0.06% | 816.79K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Baker bros. advisors lp | 654.10K | 0.25% | -653.91K |
| Bellevue group | - | - | -610.00K |
| Farallon capital management | - | - | -530.00K |
| State street | 2.49M | 0.00% | -501.46K |
| Morgan stanley | 597.68K | 0.00% | -488.25K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Orbis allan gray | 1.48M | 0.31% | 1.48M | $58.10M |
| Norges bank | 443.54K | 0.00% | 443.54K | $17.46M |
| Susquehanna fundamental investments | 92.39K | 0.05% | 92.39K | $3.64M |
| Imc-chicago | 86.47K | 0.00% | 86.47K | $3.40M |
| Raymond james financial | 82.09K | 0.00% | 82.09K | $3.23M |
Sold Out
| Holder | Change |
|---|---|
| Impact partnership wealth | -1.00 |
| Activest wealth management | -1.00 |
| Frazier financial advisors | -2.00 |
| Toronto dominion bank | -4.00 |
| Baldwin brothers llc/ma | -4.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 16 | -96.30% | 3,317,986 | -94.86% | 3 | 0.07% | 8 | -95.58% | 3 | -97.52% |
| Dec 31, 2024 | 420 | -5.83% | 64,513,268 | 8.48% | 76 | 1.57% | 174 | - | 118 | -10.61% |
| Sep 30, 2024 | 437 | -9.15% | 59,424,788 | -0.24% | 69 | 1.31% | 167 | -19.71% | 131 | 1.55% |
| Jun 30, 2024 | 478 | -7.54% | 59,547,600 | 1.78% | 72 | 1.42% | 205 | -12.02% | 129 | -9.15% |
| Mar 31, 2024 | 517 | 0.58% | 58,507,242 | 5.59% | 71 | 1.48% | 233 | -10.73% | 142 | 15.45% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| ARK Disruptive Innovation Full Composite | 7.18M | 8.37% | 743.79K |
| ARK Innovation ETF | 6.90M | 7.99% | -7.14K |
| Capital Group New Perspective Comp | 2.15M | 2.49% | -406.93K |
| American Funds New Perspective A | 2.15M | 2.49% | -406.93K |
| ARK Genomic Revolution | 2.09M | 2.44% | 299.75K |
| iShares Russell 2000 ETF | 1.99M | 2.30% | -32.12K |
| ARK Genomic Revolution ETF | 1.94M | 2.24% | -11.63K |
| American Funds SMALLCAP World A | 1.65M | 1.91% | - |
| T. Rowe Price Mid-Cap Growth | 1.49M | 1.73% | -1.10K |
| T. Rowe Price US Mid-Cap Growth Equity | 1.49M | 1.73% | -1.60K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 16, 2025 | George Simeon | - | Buy | $50.00M |
| Jul 16, 2025 | George Simeon | - | Buy | $1.16M |
| Jul 16, 2025 | George Simeon | - | Buy | $338.72K |
| May 29, 2025 | Patel Naimish | Chief Medical Officer | Sell | $141.32K |
| Mar 21, 2025 | Kulkarni Samarth | Chief Executive Officer | Sell | $413.58K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | 3 | - |
| 2025 Q2 | - | 1 |
| 2025 Q1 | 1 | 17 |
| 2024 Q4 | - | 5 |
| 2024 Q3 | - | - |
CRSP Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools